MISSION
Mirum Pharmaceuticals is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. We are passionate about advancing scientific discoveries to become important medicines for rare disease patients. We are collaborative, creative, and experienced professionals and we’re looking to augment our team with other individuals who embody our values: care, be real, get it done, and have fun, seriously.
POSITION SUMMARY
We are seeking a strategic and operationally-savvy leader to oversee and drive the program management function at Mirum, building best-in-class program management practices and strategic approaches to drive results. This leader will have responsibility for establishing program-related processes, systems, and templates to enable portfolio-level oversight and decision-making. They will lead and mentor a team of program management professionals and foster strong partnerships across internal teams to ensure program success and maximize portfolio value.
JOB FUNCTIONS/RESPONSIBILITIES
- Lead a high-performing Project Management Office that supports strategic planning and execution across all development programs.
- Establish and manage program governance to enable prioritization of resources and activities including the facilitation of annual operating plan process in conjunction with FP&A.
- Develop, implement and continuously refine PMO processes, frameworks and tools (e.g., timelines, stage-gates, communication plans, resource planning, budgeting, decision-making, etc.).
- Serve as a strategic partner and communicator with senior leadership: provide program status, decision-support, trade-offs, and portfolio linkage.
- Facilitate decision-making processes, including risk mitigation strategies and scenario planning.
- In partnership with program managers, identify key hurdles across programs.
- Identify, assess and proactively mitigate portfolio-level program risks and dependencies; escalate issues appropriately.
- Maintain continuous communication with Program Leads to ensure timely support and proactive involvement in program dynamics and team performance.
- Drive cross-functional collaboration: align stakeholders (clinical, regulatory, CMC, finance, commercial) around program strategy and deliverables.
- Mentor and develop program managers, fostering a culture of accountability, innovation, and continuous improvement.
- Coach and mentor PT members on their roles, team interactions, program deliverables & interdependencies, action plans, presentations (executive style) to senior management
- Actively resolve issues and elevate concerns with a sense of urgency to promote a culture of rapid improvement and responsiveness.
- Serve as the Program Manager for one of Mirum’s programs or during corporate development evaluation of potential new assets, as needed
QUALIFICATIONS
Education/Experience:
- Bachelor’s degree in life sciences, engineering or related field required; advanced degree (MS, PhD, MBA) strongly preferred.
- 10+ years of experience in the biotech or pharmaceutical industry, with substantive exposure to drug (or biologic/therapy) development.
- Demonstrated portfolio and program management experience with cross-functional and global teams, including milestone budget/resourcing management.
- Previous experience building a PMO is a plus.
Knowledge, Skills and Abilities:
- Deep understanding of the therapeutic development lifecycle, including non-clinical, clinical, CMC/manufacturing, regulatory and commercial interface.
- Excellent leadership, communication and interpersonal skills: ability to influence without direct authority, build relationships across functions and navigate matrix environments.
- Strong analytical and problem-solving capabilities; comfortable with ambiguity and dynamic change.
- Familiarity with program management tools and frameworks (e.g., MS Project, Smartsheet, stage-gate process).
The salary range for this position is $290,000 to $300,000 USD. Compensation will be determined based on several factors including, but not limited to; skill set, years of experience, and the employee’s geographic location. Please note that the required compensation details listed in US role postings reflect the base salary only, and do not include bonus, equity, or benefits unless otherwise provided.
#LI-HYBRID
Mirum Pharmaceuticals is committed to Equal Employment Opportunity (EEO) and to compliance with all Federal, State and Local laws that prohibit employment discrimination on the basis of race, age, national origin, ethnicity, religion, gender, gender identity, pregnancy, marital status, sexual orientation, citizenship, genetic disposition or characteristics, disability, veteran’s status or any other classification protected by applicable State/Federal/Local laws.
Mirum Pharmaceuticals provides reasonable accommodation for qualified individuals with disabilities and disabled veterans in job application procedures.
Top Skills
What We Do
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. Mirum’s approved medication is LIVMARLI® (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older.
Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. Maralixibat (LIVMARLI), an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 study for progressive familial intrahepatic cholestasis (PFIC) and the EMBARK Phase 2b study for patients with biliary atresia. In addition, Mirum has an expanded access program open in Canada, Australia, the UK and several countries in Europe for eligible patients with Alagille syndrome.
Mirum has submitted a Marketing Authorization Application to the European Medicines Agency for maralixibat for the treatment of cholestatic liver disease in patients with Alagille syndrome.
Mirum’s second investigational treatment, volixibat, also an oral IBAT inhibitor, is being evaluated in three potentially registrational studies including the OHANA Phase 2b study for pregnant women with intrahepatic cholestasis of pregnancy, VISTAS Phase 2b study for adults with primary sclerosing cholangitis, and the VANTAGE Phase 2b study for primary biliary cholangitis.
